Malignant transformation of Slp65-deficient pre-B cells involves disruption of the Arf-Mdm2-p53 tumor suppressor pathway

Blood

Volumn 115, Issue 7, 2010, Pages 1385-1393

  Ta, V B T ^a   De Bruijn, Marjolein J W ^a   Ter Brugge, Petra J ^a   Van Hamburg, Jan Piet ^a   Diepstraten, Hans J A ^a   Van Loo, Pieter Fokko ^a   Kersseboom, Rogier ^a   Hendriks, Rudi W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; ARF PROTEIN; BRUTON TYROSINE KINASE; IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN MDM2; PROTEIN P19; PROTEIN P53; SLP65 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; AGAMMAGLOBULINAEMIA TYROSINE KINASE; B CELL LINKER PROTEIN; CDKN2A PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTIDINE DEAMINASE; MDM2 PROTEIN, MOUSE; PROTEIN TYROSINE KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; CARCINOGENESIS; CONTROLLED STUDY; GENE ACTIVATION; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE C MYC; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL SURVIVAL; CELL TRANSFORMATION; CHROMOSOME; GENETICS; IMMUNOGLOBULIN VARIABLE REGION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENE; TRANSGENIC MOUSE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMES, MAMMALIAN; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYTIDINE DEAMINASE; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR CELLS, B-LYMPHOID; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-MDM2; TRANSGENES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77949898410     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-05-222166     Document Type: Article

References (51)

1. Meffre E, Casellas R, Nussenzweig MC. Antibody regulation of B-cell development. Nat Immunol. 2000;1(5):379-385.
2. Herzog S, Reth M, Jumaa H. Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling. Nat Rev Immunol. 2009;9(3):195-205.
3. Hendriks RW, Middendorp S. The pre-BCR checkpoint as a cell-autonomous proliferation switch. Trends Immunol. 2004;25(5):249-256. (Pubitemid 38501671)
4. Melchers F. The pre-B-cell receptor: selector of fitting immunoglobulin heavy chains for the B-cell repertoire. Nat Rev Immunol. 2005;5(7):578-584. (Pubitemid 40961335)
5. Jumaa H, Wollscheid B, Mitterer M, Wienands J, Reth M, Nielsen PJ. Abnormal development and function of B lymphocytes in mice deficient for the signaling adaptor protein SLP-65. Immunity. 1999;11(5):547-554.
6. Flemming A, Brummer T, Reth M, Jumaa H. The adaptor protein SLP-65 acts as a tumor suppressor that limits pre-B cell expansion. Nat Immunol. 2003;4(1):38-43. (Pubitemid 36104706)
7. Jumaa H, Mitterer M, Reth M, Nielsen PJ. The absence of SLP65 and Btk blocks B-cell development at the pre-B cell receptor-positive stage. Eur J Immunol. 2001;31(7):2164-2169. (Pubitemid 32640733)
8. Kersseboom R, Middendorp S, Dingjan GM, et al. Bruton's tyrosine kinase cooperates with the B-cell linker protein SLP-65 as a tumor suppressor in Pre-B cells. J Exp Med. 2003;198(1):91-98. (Pubitemid 36870189)
9. Hayashi K, Yamamoto M, Nojima T, Goitsuka R, Kitamura D. Distinct signaling requirements for Dmu selection, IgH allelic exclusion, pre-B cell transition, and tumor suppression in B-cell progenitors. Immunity. 2003;18(6):825-836. (Pubitemid 36780951)
10. Middendorp S, Zijlstra AJ, Kersseboom R, Dingjan GM, Jumaa H, Hendriks RW. Tumor suppressor function of Bruton tyrosine kinase is independent of its catalytic activity. Blood. 2005;105(1):259-265. (Pubitemid 40053091)
11. Jumaa H, Bossaller L, Portugal K, et al. Deficiency of the adaptor SLP-65 in pre-B cell acute lymphoblastic leukaemia. Nature. 2003;423(6938):452-456. (Pubitemid 36626998)
12. Klein F, Feldhahn N, Harder L, et al. The BCR-ABL1 kinase bypasses selection for the expression of a pre-B cell receptor in pre-B acute lymphoblastic leukemia cells. J Exp Med. 2004;199(5):673-685. (Pubitemid 38316434)
13. Imai C, Ross ME, Reid G, et al. Expression of the adaptor protein BLNK/SLP-65 in childhood acute lymphoblastic leukemia. Leukemia. 2004;18(5):922-925. (Pubitemid 38714615)
14. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446(7137):758-764. (Pubitemid 46582031)
15. Nakayama J, Yamamoto M, Hayashi K, et al. BLNK suppresses pre-B cell leukemogenesis through inhibition of JAK3. Blood. 2009;113(7):1483-1492.
16. Morrow MA, Lee G, Gillis S, Yancopoulos GD, Alt FW. Interleukin-7 induces N-myc and c-myc expression in normal precursor B lymphocytes. Genes Dev. 1992;6(1):61-70.
17. Lu L, Chaudhury P, Osmond DG. Regulation of cell survival during B lymphopoiesis: apoptosis and Bcl-2/Bax content of precursor B cells in bone marrow of mice with altered expression of IL-7 and recombinase-activating gene-2. J Immunol. 1999;162(4):1931-1940. (Pubitemid 29288808)
18. Dillon SR, Schlissel MS. Partial restoration of B-cell development in Jak-3(-/-) mice achieved by co-expression of IgH and E(mu)-myc transgenes. Int Immunol. 2002;14(8):893-904.
19. Adams JM, Harris AW, Pinkert CA, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 12-18. 1985;318(6046):533-538.
20. Habib T, Park H, Tsang M, et al. Myc stimulates B lymphocyte differentiation and amplifies calcium signaling. J Cell Biol. 2007;179(4):717-731. (Pubitemid 350146257)
21. Wen R, Chen Y, Bai L, et al. Essential role of phospholipase C gamma 2 in early B-cell development and Myc-mediated lymphomagenesis. Mol Cell Biol. 2006;26(24):9364-9376.
22. Sherr CJ. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 1998;12(19):2984-2991. (Pubitemid 28469300)
23. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999;13(20):2658-2669.
24. Hendriks RW, de Bruijn MF, Maas A, Dingjan GM, Karis A, Grosveld F. Inactivation of Btk by insertion of lacZ reveals defects in B-cell development only past the pre-B cell stage. EMBO J. 1996;15(18):4862-4872. (Pubitemid 26315797)
25. Strasser A, Whittingham S, Vaux DL, et al. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci U S A. 1991;88(19):8661-8665.
26. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356(6366):215-221.
27. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 2000;102(5):553-563.
28. Martin F, Won WJ, Kearney JF. Generation of the germline peripheral B-cell repertoire: VH81X-lambda B cells are unable to complete all developmental programs. J Immunol. 1998;160(8):3748-3758. (Pubitemid 28176077)
29. Middendorp S, Dingjan GM, Hendriks RW. Impaired precursor B-cell differentiation in Bruton's tyrosine kinase-deficient mice. J Immunol. 2002;168(6):2695-2703. (Pubitemid 34211646)
30. Kersseboom R, Ta VB, Zijlstra AJ, et al. Bruton's tyrosine kinase and SLP-65 regulate pre-B cell differentiation and the induction of Ig light chain gene rearrangement. J Immunol. 2006;176(8):4543-4552.
31. Nussenzweig MC, Schmidt EV, Shaw AC, et al. A human immunoglobulin gene reduces the incidence of lymphomas in c-Myc-bearing transgenic mice. Nature. 1988;336(6198):446-450.
32. Roth DB. Restraining the V(D)J recombinase. Nat Rev Immunol. 2003;3(8):656-666.
33. Feldhahn N, Henke N, Melchior K, et al. Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells. J Exp Med. 2007;204(5):1157-1166. (Pubitemid 46798158)
34. Wang CL, Harper RA, Wabl M. Genome-wide somatic hypermutation. Proc Natl Acad Sci U S A. 2004;101(19):7352-7356.
35. Voncken JW, Morris C, Pattengale P, et al. Clonal development and karyotype evolution during leukemogenesis of BCR/ABL transgenic mice. Blood. 1992;79(4):1029-1036.
36. Rooney S, Sekiguchi J, Whitlow S, et al. Artemis and p53 cooperate to suppress oncogenic N-myc amplification in progenitor B cells. Proc Natl Acad Sci U S A. 2004;101(8):2410-2415. (Pubitemid 38269325)
37. Difilippantonio MJ, Petersen S, Chen HT, et al. Evidence for replicative repair of DNA double-strand breaks leading to oncogenic translocation and gene amplification. J Exp Med. 2002;196(4):469-480.
38. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev. 1996;10(9):1054-1072.
39. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer. 2002;2(8):594-604. (Pubitemid 37328926)
40. Sherr CJ. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer. 2006;6(9):663-673.
41. Wang P, Lushnikova T, Odvody J, Greiner TC, Jones SN, Eischen CM. Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells. Oncogene. 2008;27(11):1590-1598.
42. Arakawa H, Takeda S. Early expression of Ig mu chain from a transgene significantly reduces the duration of the pro-B stage but does not affect the small pre-B stage. Int Immunol. 1996;8(8):1319-1328. (Pubitemid 26289911)
43. Sprangers M, Feldhahn N, Liedtke S, Jumaa H, Siebert R, Muschen M. SLP65 deficiency results in perpetual V(D)J recombinase activity in pre-B lymphoblastic leukemia and B-cell lymphoma cells. Oncogene. 2006;25(37):5180- 5186. (Pubitemid 44285987)
44. Nepal RM, Zaheen A, Basit W, Li L, Berger SA, Martin A. AID and RAG1 do not contribute to lymphomagenesis in Emu c-myc transgenic mice. Oncogene. 2008;27(34):4752-4756.
45. Köhler F, Hug E, Eschbach C, et al. Autoreactive B-cell receptors mimic autonomous pre-B cell receptor signaling and induce proliferation of early B cells. Immunity. 2008;29(6):912-921.
46. Humbey O, Pimkina J, Zilfou JT, et al. The ARF tumor suppressor can promote the progression of some tumors. Cancer Res. 2008;68(23):9608-9613.
47. Bouchard C, Lee S, Paulus-Hock V, Loddenkemper C, Eilers M, Schmitt CA. FoxO transcription factors suppress Myc-driven lymphomagenesis via direct activation of Arf. Genes Dev. 2007;21(21):2775-2787. (Pubitemid 350070723)
48. Radfar A, Unnikrishnan I, Lee HW, DePinho RA, Rosenberg N. p19(Arf) induces p53-dependent apoptosis during Abelson virus-mediated pre-B cell transformation. Proc Natl Acad Sci U S A. 1998;95(22):13194-13199.
49. Sulong S, Moorman AV, Irving JA, et al. A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups. Blood. 2009;113(1):100-107.
50. Mullighan CG, Phillips LA, Su X, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science. 2008;322(5906):1377- 1380. (Pubitemid 352775249)
51. Zhou M, Yeager AM, Smith SD, Findley HW. Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood. 1995;85(6):1608-1614.